BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Opinion

  The Urgent Need To Redefine the Future of UK Biotech

  As major pharmas pull away from the U.K. and the U.S. risks ceding its lead through a national brain drain, the U.K. must create a new, more robust model for innovation.

  October 1, 2025

   · 

  6 min read

   · 

  Kerstin Papenfuss
• 

  Mergers & acquisitions

  The Top Big Pharmas Have $1.2T in Stretch M&A Firepower Available

  The two most historically deal-conservative Big Pharmas have the most money to play with for a major M&A transaction, according to a recent Stifel analysis.

  October 1, 2025

   · 

  6 min read

   · 

  Annalee Armstrong
• 

  Mergers & acquisitions

  Just 9.5% of Life Sciences M&A Milestones Have Been Paid Since 2008

  A new analysis from SRS Acquiom puts into perspective the headline values seen when a company announces a backloaded M&A deal. Biotechs have much on the line when they agree to deals with massive potential but little upfront.

  October 1, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Government

  How the UK’s ‘Credibility Challenge’ Hinders Attempts To Reverse Pharma’s Flight

  Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, contributing to a pullback in investment.

  October 1, 2025

   · 

  4 min read

   · 

  Nick Paul Taylor
• Press Releases

  Liquid Filtration for Pharmaceutical Market Competitive and Value Chain Analysis Insight

  October 1, 2025

   · 

  1 min read
• Press Releases

  Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

  October 1, 2025

   · 

  5 min read
• Press Releases

  Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia

  October 1, 2025

   · 

  3 min read
• Press Releases

  Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

  October 1, 2025

   · 

  9 min read
• Press Releases

  LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

  October 1, 2025

   · 

  7 min read
• Press Releases

  Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

  October 1, 2025

   · 

  6 min read